We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




PCR Panels for Acute GI Infections Can Lower Costs, Hospitalization and Antibiotic Use

By LabMedica International staff writers
Posted on 16 Mar 2023

Acute gastroenteritis impacts adults across all age groups and incurs enormous healthcare expenses. More...

Now, a new study comprising 40,000 hospital visits across various geographic locations has revealed that a single stool sample analysis using multiple polymerase chain reaction (PCR) panels is capable of identifying more pathogens, especially diarrhea-causing E. coli and enteric viruses, faster than a traditional diagnostic workup.

Research conducted by the University of Washington School of Medicine (Seattle, WA, USA) found that the application of multiplex PCR resulted in a higher number of patients being discharged, reducing hospitalization rates during the following month. The cost of care for these patients was similar to those undergoing traditional stool work-up along with follow-up visits. Typically, conventional workups involve testing a stool culture for a single suspect species of pathogen, using a single pathogen PCR test or identifying a pathogen with the help of microscopy, immunology or an ova and parasites test. Additionally, the researchers found that using multiplex PCR (consisting of 12 or more panels) led to a decrease in the administration of antibiotics to hospitalized patients.

“Earlier studies showed that large multiplex PCR panels improve the speed and accuracy of diagnostic testing in patients with acute gastroenteritis, but their impact on costs and clinical outcomes had been uncertain,” said Ferric C. Fang, M.D., Professor of Laboratory Medicine, Pathology and Microbiology at the University of Washington School of Medicine, Seattle. “Our study shows that the benefits of multiplex panels can be achieved without increasing overall healthcare costs, and also facilitates more appropriate use of antibiotics.”

“This study illustrates the power of big data to analyze the healthcare impacts of diagnostic testing and help laboratories select testing approaches that improve meaningful clinical outcomes,” Fang said.

Related Links:
University of Washington School of Medicine 


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.